TJ275B - Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof - Google Patents

Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof

Info

Publication number
TJ275B
TJ275B TJ96000377A TJ96000377A TJ275B TJ 275 B TJ275 B TJ 275B TJ 96000377 A TJ96000377 A TJ 96000377A TJ 96000377 A TJ96000377 A TJ 96000377A TJ 275 B TJ275 B TJ 275B
Authority
TJ
Tajikistan
Prior art keywords
derivatives
enhenced
cyclodextrins
exhibiting
aqueous solubility
Prior art date
Application number
TJ96000377A
Inventor
Valentino J Stella
Roger Rajewski
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25440795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ275(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of TJ275B publication Critical patent/TJ275B/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
TJ96000377A 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof TJ275B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/918,702 US5376645A (en) 1990-01-23 1992-07-27 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
PCT/US1993/006880 WO1994002518A1 (en) 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Publications (1)

Publication Number Publication Date
TJ275B true TJ275B (en) 2000-10-05

Family

ID=25440795

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000377A TJ275B (en) 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof

Country Status (16)

Country Link
US (1) US5376645A (en)
EP (1) EP0620828B2 (en)
JP (1) JP3393253B2 (en)
KR (1) KR100279111B1 (en)
AT (1) ATE217325T1 (en)
AU (1) AU672814B2 (en)
CA (1) CA2119154C (en)
DE (1) DE69331900T3 (en)
DK (1) DK0620828T4 (en)
ES (1) ES2176206T5 (en)
GE (1) GEP19991649B (en)
MD (1) MD1813C2 (en)
PT (1) PT620828E (en)
RU (1) RU2113442C1 (en)
TJ (1) TJ275B (en)
WO (1) WO1994002518A1 (en)

Families Citing this family (579)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co An aqueous nasal suspension comprising cyclodextrin
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
DE69733664T3 (en) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Method of inactivating viruses and lyophilizing blood proteins
UA57734C2 (en) 1996-05-07 2003-07-15 Пфайзер Інк. Arylheterocyclic inclusion complexes
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
ES2207748T3 (en) * 1996-08-09 2004-06-01 Alcon Manufacturing Ltd. PRESERVING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINES.
DE19716120A1 (en) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Use of cholesterol-lowering agents
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
JP4439596B2 (en) * 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク． Pharmaceutical composition containing polar drug or polar prodrug having long shelf life, and method for producing the same
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
DK0889056T3 (en) * 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
US6596706B1 (en) * 1997-11-07 2003-07-22 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
AU759280C (en) * 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
FR2784584B1 (en) * 1998-10-14 2002-09-20 Adir PROCESS FOR THE PREPARATION OF A NASAL SPRAY SOLUTION CONTAINING ONE OR MORE SEXUAL HORMONES AND A CYCLODEXTRIN
ATE356637T1 (en) * 1998-12-04 2007-04-15 California Inst Of Techn DRUGS CONTAINING SUPRAMOLECULAR COMPLEXES
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
EP1143796A4 (en) 1999-01-21 2002-03-20 Bristol Myers Squibb Co Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
CA2726789A1 (en) * 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
ES2253364T3 (en) * 2000-03-28 2006-06-01 Farmarc Nederland B.V. INCLUSION COMPLEXES OF ALPRAZOLAM AND ITS PHARMACEUTICAL COMPOSITIONS.
SK286129B6 (en) 2000-05-26 2008-04-07 Pfizer Inc. Tropane derivatives, their use, a method for their preparation, an intermediate, a combination and a pharmaceutical composition containing thereof
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
KR100856523B1 (en) * 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20020300A1 (en) * 2000-08-22 2002-05-10 Pharmacia Corp COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (en) 2000-10-10 2003-09-10 Upjohn Co TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
AU2002241823A1 (en) * 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EE05400B1 (en) 2001-04-10 2011-04-15 Pfizer Inc. Prazole derivatives, pharmaceutical compositions containing them or their pharmaceutically acceptable salts, solvates or derivatives, their use and methods for their preparation
NZ528886A (en) * 2001-05-01 2005-04-29 Pfizer Prod Inc A dry process for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7008934B2 (en) * 2001-06-28 2006-03-07 Baxter International Inc. Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
JP2004522803A (en) * 2001-06-29 2004-07-29 マキシゲン・エイピーエス Interferon preparation
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
US20040198698A1 (en) * 2001-07-20 2004-10-07 Walter Heinzelmann Nitrate ester-cyclodextrin complexes
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
DE60322665D1 (en) 2002-02-01 2008-09-18 Pfizer Prod Inc PHARMACEUTICAL PHARMACEUTICAL FORM WITH CONTROLLED RELEASE OF A CHOLESTERYL SAMPLE TRANSFER PROTEIN INHIBITOR
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
AU2003245711A1 (en) 2002-02-11 2003-09-04 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
AR038575A1 (en) * 2002-02-22 2005-01-19 Pharmacia Corp OPHTHALM FORMULATION WITH NEW RUBBER COMPOSITION
MXPA04008173A (en) * 2002-02-22 2004-11-26 Pharmacia Corp Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride.
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
BR0313602A (en) * 2002-08-20 2005-06-21 Bristol Myers Squibb Co Aripiprazole Complex Method and Formulation
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
CN102516417B (en) 2002-09-06 2014-12-10 天蓝制药公司 Cyclodextrin-based polymers for therapeutics delivery
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
MXPA05002728A (en) * 2002-09-13 2005-07-25 Cydex Inc Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin.
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd Transdermal delivery system for anti-emetic medication
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
KR20050085563A (en) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2004206842A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP2289488A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
CL2004000826A1 (en) 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
WO2005023257A1 (en) 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
CA2537127C (en) 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
BRPI0414343A (en) 2003-09-12 2006-11-07 Pfizer combinations comprising alpha-2-delta ligands and serotonin / norepinephrine reuptake inhibitors
AU2004278158B2 (en) 2003-10-03 2009-08-13 Pfizer Inc. Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
JP5619337B2 (en) 2003-10-10 2014-11-05 フェリング ビー．ブイ． Transdermal pharmaceutical formulation to minimize skin residue
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
KR20070007075A (en) * 2003-12-31 2007-01-12 사이덱스 인크 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
ATE369333T1 (en) 2004-01-22 2007-08-15 Pfizer SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
ES2293530T3 (en) 2004-01-22 2008-03-16 Pfizer, Inc. DERIVATIVES OF SULFONAMIDS FOR THE TREATMENT OF DISEASES.
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
EP1735284A1 (en) 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
WO2005092840A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Formamide derivatives useful as adrenoceptor
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
CN103554222A (en) 2004-04-15 2014-02-05 欧尼斯治疗公司 Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
AU2005237523A1 (en) * 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
MXPA06012505A (en) 2004-04-30 2006-12-15 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders.
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
SI2030981T1 (en) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
NZ552868A (en) 2004-08-12 2009-07-31 Pfizer Triazolopyridinylsulfanyl derivatives as P38 MAP kinase inhibitors
ES2341351T3 (en) 2004-08-26 2010-06-18 Pfizer, Inc. ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS PROTEIN CINASE INHIBITORS.
ITMI20041763A1 (en) * 2004-09-16 2004-12-16 Altergon Sa NEW INJECTABLE FORMULATIONS CONTAINING PROGESTERONE
BRPI0517925A (en) 2004-11-02 2008-10-21 Pfizer sulfonyl benzimidazole derivatives
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
GT200500317A (en) * 2004-11-05 2006-10-27 PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
PT2261236E (en) * 2004-12-07 2015-10-30 Onyx Therapeutics Inc Composition for proteasome inhibition
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US8703099B2 (en) 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
EA200701745A1 (en) 2005-03-17 2008-06-30 Пфайзер, Инк. CYCLOPROPANKARCARBOXAMID DERIVATIVES
DE602006003416D1 (en) 2005-03-21 2008-12-11 Pfizer Ltd SUBSTITUTED TRIAZONE DERIVATIVES AS OXYTOCINANTAGONISTS
EP2494965A3 (en) * 2005-04-15 2013-01-02 The Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy
US8076293B2 (en) 2005-04-19 2011-12-13 Gabriel Stavros Panayi Use of BiP or a variant, homologue, derivative or fragment thereof in the manufacture of a medicament for the prevention or treatment of bone loss or bone resorption
BRPI0609952A2 (en) * 2005-04-24 2010-05-11 Wyeth Corp Methods to Modulate Bladder Function
EA200702235A1 (en) 2005-05-04 2008-04-28 Пфайзер Лимитед DERIVATIVES OF 2-AMIDO-6-AMINO-8-OXOPURIN AS MODULATORS OF TOLL-SIMILAR RECEPTORS FOR TREATING CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
BRPI0611798A2 (en) 2005-06-15 2009-01-13 Pfizer Ltd substituted arylpyrazole compounds, their pharmaceutical composition and use
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AR054849A1 (en) * 2005-07-26 2007-07-18 Wyeth Corp DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
DE102005041860A1 (en) * 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
AU2006299501B2 (en) 2005-09-30 2012-11-29 Lundbeck Llc Novel parenteral carbamazepine formulation
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
DK2952197T3 (en) 2005-10-26 2017-08-07 Cydex Pharmaceuticals Inc SULPHALYCYLETER CYCLE CODE EXTRACTION COMPOSITION AND PROCEDURE FOR PREPARING THEREOF
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
NL2000323C2 (en) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
JP2009520828A (en) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー Systems and methods for delivering corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
EP1993598A2 (en) * 2006-02-15 2008-11-26 Tika Läkemedel AB Methods of manufacturing corticosteroid solutions
US20070225278A1 (en) * 2006-03-24 2007-09-27 Wyeth Methods for treating cognitive and other disorders
CN101448492A (en) * 2006-03-24 2009-06-03 惠氏公司 Methods for treating cognitive and other disorders
CN101410118A (en) * 2006-03-24 2009-04-15 惠氏公司 Treatment of pain
CA2644662A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
WO2007112073A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
MX2008013407A (en) * 2006-04-18 2009-03-09 Ekr Therapeutics Inc Pre-mixed, ready-to-use iv bolus compositions and methods of use.
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CN100374468C (en) * 2006-05-25 2008-03-12 重庆通量精细化工有限公司 Synthetic process for water soluble sulfoalkyl ether-beta-cyclic dextrine
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
AR061889A1 (en) 2006-07-13 2008-10-01 Medichem Sa IMPROVED PROCESS FOR THE PREPARATION OF VORICONAZOL
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
AU2007286651A1 (en) 2006-08-23 2008-02-28 Intellect Neurosciences Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
US20080194519A1 (en) * 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
EP2068853A2 (en) 2006-09-15 2009-06-17 Stevia APS Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo[3.2.1]octans such as steviol and isosteviol
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
WO2008035195A1 (en) 2006-09-21 2008-03-27 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
KR20090069330A (en) 2006-10-12 2009-06-30 와이어쓰 Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
PL2076508T3 (en) 2006-10-18 2011-05-31 Pfizer Prod Inc Biaryl ether urea compounds
MX2009004214A (en) 2006-10-20 2009-05-11 Icos Corp Compositions of chk1 inhibitors.
ATE520651T1 (en) 2006-10-23 2011-09-15 Pfizer SUBSTITUTED PHENYLMETHYLBICYCLOCARBONIC ACID AMIDE COMPOUNDS
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
KR100822133B1 (en) * 2006-11-06 2008-04-15 한미약품 주식회사 Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
MX2009005368A (en) * 2006-11-21 2009-06-05 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure.
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
RU2009132986A (en) 2007-03-02 2011-04-10 Уайт (Us) APPLICATION OF COPPER AND GLUTAMATE IN CULTURE OF CELLS FOR THE PRODUCTION OF POLYPEPTIDES
ES2373867T3 (en) * 2007-03-02 2012-02-09 The University Of Wollongong COMPOSITIONS AND PROCEDURES FOR THE SUPPLY OF ANTI-TARGET AGENTS.
RU2470636C2 (en) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Composition of clopidogrel and sulphoalkylester cyclodextrin (versions) and methods of treating diseases by said composition (versions)
AU2015255164B2 (en) * 2007-04-27 2017-06-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
RU2450017C2 (en) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Hydantoin modified melanocortin receptor ligands
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
TWI428132B (en) 2007-07-02 2014-03-01 Lilly Co Eli Potentiation of cancer chemotherapy
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
AU2008294473B2 (en) 2007-09-05 2013-12-05 Rigel Pharmaceuticals, Inc. Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one) -6-yl]-5-fluoro-N2-[3-methylaminocar-bonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
KR100929920B1 (en) 2007-09-05 2009-12-04 주식회사 마크로케어 Method for preparing clathrate containing hydrophobic physiologically active ingredient in cyclodextrin and derivatives thereof and use of clathrate prepared thereby
CL2008002777A1 (en) * 2007-09-21 2010-01-22 Wyeth Corp Method of preparing chiral diazepinoquinoline compounds by recrystallization in a ternary solvent system.
KR20170125413A (en) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
JP5643195B2 (en) * 2008-06-16 2014-12-17 デビオファーム インターナショナル ソシエテ アノニム Concentrated oxaliplatin solution and preparation method thereof
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
ES2378513T3 (en) 2008-08-06 2012-04-13 Pfizer Inc. Compounds 2-heterocyclylamino pyrazines substituted in position 6 as inhibitors of CHK-1
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2741312C (en) 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
MY194407A (en) 2008-11-15 2022-11-30 Melinta Subsidiary Corp Antimicrobial Compositions
EP2386546B1 (en) 2008-11-21 2015-08-19 RaQualia Pharma Inc Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity
AU2009335788A1 (en) 2008-12-17 2011-07-07 Genentech, Inc. Hepatitis C virus combination therapy
BRPI1006128A2 (en) 2009-01-12 2016-11-01 Cagen Inc sulfonamide derivatives
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
CN102348718B (en) 2009-01-14 2015-06-03 诺瓦克塔生物系统有限公司 Deoxyactagardine derivatives
EP2393829A1 (en) 2009-02-04 2011-12-14 Novacta Biosystems Limited Actagardine derivatives
AU2010223268B2 (en) 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
PT3100728T (en) 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
EP2435462A1 (en) 2009-05-29 2012-04-04 Pfizer Limited Novel glucocorticoid receptor agonists
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
PT2442791T (en) 2009-06-16 2020-02-06 Pfizer Dosage forms of apixaban
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
JP5919196B2 (en) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Use of peptide epoxy ketones for metastasis inhibition
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
PE20130188A1 (en) 2009-12-23 2013-02-21 Takeda Pharmaceutical HETEROAROMATIC PYRROLIDINONES FUSED AS SYK INHIBITORS
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
KR101747476B1 (en) 2010-01-21 2017-06-14 드로브리지 파마슈티컬스 피티와이 엘티디 Anaesthetic formulation
CA2789164A1 (en) 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
WO2011104649A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
RU2552927C2 (en) * 2010-03-13 2015-06-10 Истпонд Лабораториз Лимитед Fat-biding composition
MX2012011604A (en) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor.
JP2013525476A (en) 2010-05-04 2013-06-20 ファイザー・インク Heterocyclic derivatives as ALK inhibitors
RU2627460C2 (en) 2010-05-26 2017-08-08 Нейрофиксиа Б.В. Formulations of 2-iminobiotine and use thereof
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011156481A2 (en) * 2010-06-11 2011-12-15 Baxter International Inc. Formulations including amiodarone and salts thereof and methods of their manufacture and use
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013536165A (en) 2010-07-12 2013-09-19 ファイザー・リミテッド Sulfonamide derivatives as NAV 1.7 inhibitors for the treatment of pain
JP2013532184A (en) 2010-07-12 2013-08-15 ファイザー・リミテッド N-sulfonylbenzamide derivatives useful as voltage-gated sodium channel inhibitors
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532185A (en) 2010-07-12 2013-08-15 ファイザー・リミテッド Compound
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
US9453040B2 (en) 2010-08-24 2016-09-27 Imperial Innovations Limited Glycodendrimers of polypropyletherimine
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
RU2564445C2 (en) 2010-11-15 2015-10-10 ВииВ Хелткер ЮКей Лимитед Inhibitors of hiv replication
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP3388066B1 (en) 2011-01-26 2020-11-04 Allergan, Inc. Androgen composition for treating an opthalmic condition
AR085406A1 (en) 2011-02-25 2013-09-25 Takeda Pharmaceutical N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTERIDINONES
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
AU2012238369A1 (en) 2011-04-05 2013-10-03 Pfizer Limited Pyrrolo (2, 3 -d) pyrimidine derivatives as inhibitors of tropomyosin- related kinases
EP2710002B1 (en) 2011-05-18 2017-03-01 RaQualia Pharma Inc Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
TWI544922B (en) 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
RU2566262C2 (en) 2011-06-15 2015-10-20 Синтон Бв Stabilised voriconazole composition
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
US8957025B2 (en) 2011-07-13 2015-02-17 Pfizer Inc. Enkephalin analogues
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2739274A1 (en) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Treatment of cognitive impairment
KR20140041906A (en) 2011-08-02 2014-04-04 화이자 인코포레이티드 Crizotinib for use in the treatment of cancer
DK2753632T3 (en) 2011-09-08 2023-07-10 Sage Therapeutics Inc NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF
US9376395B2 (en) 2011-09-18 2016-06-28 Purdue Pharmaceuticals Products L.P. Pharmaceutical compositions
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP3572417A3 (en) 2011-10-14 2020-03-25 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
JP5363636B2 (en) 2011-10-21 2013-12-11 ファイザー・リミテッド New salts and medical uses
CN103906746B (en) 2011-10-26 2015-12-09 辉瑞有限公司 As (4-phenylimidazole-2-base) 1-ethanamine derivatives of sodium channel modulators
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
TW201332572A (en) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd Pharmaceutical preparation comprising substituted β -cyclodextrin
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
TWI573792B (en) 2012-02-01 2017-03-11 歐陸斯迪公司 Novel therapeutic agents
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (en) 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
CN104271605B (en) 2012-02-15 2017-07-25 锡德克斯药物公司 The manufacture method of cyclodextrine derivatives
JP2015508846A (en) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド Alkylated cyclodextrin compositions and methods for their preparation and use
JP5823066B2 (en) 2012-03-06 2015-11-25 ファイザー・インク Macrocyclic derivatives for the treatment of proliferative diseases
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CA2869056C (en) 2012-03-30 2020-02-25 Sapiotec Gmbh Anthocyanidin complex
JP2015524394A (en) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Prodrugs of peptide epoxyketone protease inhibitors
UY34893A (en) 2012-07-10 2014-02-28 Takeda Pharmaceutical DERIVATIVES OF AZAINDOL
CN107865968B (en) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) Cyclodextrins for the treatment of lysosomal storage disorders
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
CA2884921A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
EP2900653A1 (en) 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
EP2903986A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-related kinase inhibitors
CN104780925A (en) * 2012-10-17 2015-07-15 赛博尔泰克股份公司 Anthocyanidin complex for the treatment of multiple myeloma
BR112015008954B1 (en) 2012-10-22 2021-03-02 Cydex Pharmaceuticals, Inc processes for preparing an alkylated cyclodextrin composition comprising an alkylated cyclodextrin, for preparing at least 9 consecutive batches thereof and for preparing a pharmaceutical composition
PE20150966A1 (en) 2012-11-08 2015-06-21 Pfizer HETEROAROMATIC COMPOUNDS AND THEIR USE AS D1 LIGANDS OF DOPAMINE
BR112015010620A2 (en) 2012-11-08 2017-07-11 Pfizer heteroaromatic compounds and their uses as dopamine d1 binders
KR102147084B1 (en) * 2012-11-15 2020-08-24 자피오텍 게엠베하 Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
RU2659036C2 (en) 2012-11-21 2018-06-27 Раквалиа Фарма Инк. Polymorphic forms
DK2925725T3 (en) 2012-12-03 2017-01-16 Pfizer androgen receptor modulators
EP2931287B1 (en) * 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin for combating melanoma cells
UA112028C2 (en) 2012-12-14 2016-07-11 Пфайзер Лімітед IMIDAZOPYRIDASINE DERIVATIVES AS HAMBA-RECEPTOR MODULATORS
UA111305C2 (en) 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
SG11201505680RA (en) 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
JO3377B1 (en) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co Pyridinyl and fused pyridinyl triazolone derivatives
AU2014243819A1 (en) 2013-03-13 2015-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2886506T3 (en) 2013-03-13 2021-12-20 Sage Therapeutics Inc neuroactive steroids
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
KR102239541B1 (en) 2013-04-17 2021-04-14 세이지 테라퓨틱스, 인크. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
RU2700264C2 (en) 2013-04-17 2019-09-16 Сейдж Терапьютикс, Инк. 19-nor neuroactive steroids and methods of using them
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
TW201443025A (en) 2013-04-19 2014-11-16 Pfizer Ltd Chemical compounds
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
RU2016103764A (en) 2013-07-08 2017-08-11 Эббви Инк. STABILIZED PHARMACEUTICAL MEDICINES CONTAINING ATRASENTAN
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3488852T (en) 2013-08-23 2021-02-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (en) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 Macrocyclic compounds for the treatment of proliferative diseases
RU2572334C2 (en) * 2013-12-06 2016-01-10 Общество С Ограниченной Ответственностью "Луфатен" Clathrate complex of arabinogalactan or arabic gum with 20-hydroxyecdysones, method for producing it (versions), pharmaceutical composition and medicinal product
JP2016540811A (en) 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ N-acyl piperidine ether tropomyosin related kinase inhibitor
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
TW201620904A (en) 2014-01-09 2016-06-16 武田藥品工業有限公司 Azaindole derivatives
CN104971355B (en) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 Composition containing razaxaban and preparation method thereof
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
AP2016009464A0 (en) 2014-04-25 2016-09-30 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
CN107074843A (en) 2014-04-25 2017-08-18 辉瑞公司 Heteroaromatics and its purposes as dopamine D 1 part
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
JP6564394B2 (en) 2014-04-28 2019-08-21 ファイザー・インク Heterocyclic compounds and their use as dopamine D1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
EP3143021B1 (en) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
AU2015260906B2 (en) 2014-05-15 2017-08-31 Pfizer Inc. Crystalline form of 6-((4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile
MX366985B (en) 2014-05-20 2019-08-01 Raqualia Pharma Inc Benzisoxazole derivative salt.
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
ES2927007T3 (en) 2014-05-29 2022-10-31 Sage Therapeutics Inc Neuroactive steroids, compositions and uses thereof
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US20170275275A1 (en) 2014-05-30 2017-09-28 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
WO2015189744A1 (en) 2014-06-12 2015-12-17 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
PE20161552A1 (en) 2014-06-17 2017-01-11 Pfizer SUBSTITUTE DIHYDROISOQUINOLINONE COMPOUNDS
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2015277554C1 (en) 2014-06-18 2018-05-31 Audevard Transdermal formulations of pergolide and uses thereof
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
FI3183295T3 (en) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
JOP20200195A1 (en) 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
CN112121171A (en) 2014-10-07 2020-12-25 萨奇治疗股份有限公司 Neuroactive compounds and methods of use thereof
BR112017007902B1 (en) 2014-10-16 2023-12-05 Sage Therapeutics, Inc COMPOUND AND ITS SALT, PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND AND ITS SALT IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
LT3206493T (en) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
SI3224269T1 (en) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
TW201636342A (en) 2014-12-19 2016-10-16 武田藥品工業有限公司 Fumagillol derivatives
CA2977421C (en) 2015-01-22 2022-10-18 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
PL3253208T3 (en) 2015-02-02 2021-11-08 Mei Pharma, Inc. Combination therapies for use in the treatment of breast cancer
CN107427458A (en) 2015-02-06 2017-12-01 马瑞纳斯制药公司 Intravenous ganaxolone preparation and its purposes in treatment status epilepticus and other seizure disorders
JP6875996B2 (en) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド Neurostimulatory steroids, compositions, and their use
MX2017010844A (en) 2015-02-24 2017-12-07 Pfizer Substituted nucleoside derivatives useful as anticancer agents.
CA2979527A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
CA2980170A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
KR20180035787A (en) 2015-06-10 2018-04-06 브이테스, 인코포레이티드 Hydroxypropylbeta-cyclodextrin compositions and methods
JP6882996B2 (en) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド Oxysterols and how to use them
AU2016289967B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055199T2 (en) 2015-07-06 2021-11-29 Sage Therapeutics Inc Oxysterols and methods of use thereof
US20170007617A1 (en) 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
AU2016304408B2 (en) 2015-07-31 2019-02-21 Pfizer Inc., 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2017098367A1 (en) 2015-12-10 2017-06-15 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
SG11201805331QA (en) 2015-12-24 2018-07-30 Takeda Pharmaceuticals Co Cocrystal, production method thereof, and medicament containing cocrystal
TWI726968B (en) 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
EP3402796B1 (en) 2016-01-15 2020-11-18 Pfizer Inc 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
JP2019512538A (en) 2016-02-18 2019-05-16 メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Oritavancin formulation
AU2017224249A1 (en) 2016-02-28 2018-09-13 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
JP7112957B2 (en) 2016-03-09 2022-08-04 ベイジン パーカンズ オンコロジー カンパニー リミテッド Tumor cell suspension culture and related methods
WO2017173111A1 (en) * 2016-03-31 2017-10-05 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
SI3436022T1 (en) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
MA45598B1 (en) 2016-07-07 2021-09-30 Sage Therapeutics Inc 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
DK3481844T3 (en) 2016-07-11 2024-07-22 Sage Therapeutics Inc C7, C12 and C16 substituted neuroactive steroids and their methods of use
MA45599A (en) 2016-07-11 2019-05-15 Sage Therapeutics Inc NEUROACTIVE STEROIDS SUBSTITUTED FOR C17, C20 AND C21 AND THEIR USE PROCEDURES
JP2019532021A (en) 2016-07-29 2019-11-07 ファイザー・インク Cyclic peptides as C5a receptor antagonists
KR102518846B1 (en) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. Methods and compositions for the treatment of epileptic disorders
CN109803968A (en) 2016-08-15 2019-05-24 辉瑞公司 Pyridopyrimidinone CDK2/4/6 inhibitor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
TWI815800B (en) 2016-10-18 2023-09-21 美商賽吉醫療公司 Oxysterols and methods of use thereof
EP3529256B1 (en) 2016-10-18 2023-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
JP7273723B2 (en) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド Novel quinazolinones that inhibit the formation of tau oligomers and methods of use thereof
BR112019014688A2 (en) 2017-01-20 2020-02-18 Pfizer Inc. 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-IL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
JP6778833B2 (en) 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． (Hetero) arylamide compounds for suppressing kinase activity
ES2864405T3 (en) 2017-01-20 2021-10-13 Shenzhen Targetrx Inc Composed of (hetero) arylamide to inhibit protein kinase activity
MX2019008690A (en) 2017-01-23 2019-09-18 Pfizer Heterocyclic spiro compounds as magl inhibitors.
US11274164B2 (en) 2017-02-07 2022-03-15 Biophore India Pharmaceuticals Pvt. Ltd. Method for the preparation of sulfobutylether beta cyclodextrin sodium
ES2968462T3 (en) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Polymorphic salt of 6-chloro-3-amino-2(2-hydroxyprolyl) quinoline and uses thereof
WO2018183145A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
WO2018177403A1 (en) 2017-04-01 2018-10-04 成都优赛丽医药科技有限公司 1h-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
EP3618825A4 (en) 2017-05-03 2021-01-20 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
JOP20180057A1 (en) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co Tetrahydropyridopyrazine modulators of gpr6
MX2019015468A (en) 2017-06-22 2020-08-03 Curadev Pharma Ltd Small molecule modulators of human sting.
CN108658983B (en) 2017-06-26 2019-12-20 深圳市塔吉瑞生物医药有限公司 N-benzenesulfonyl benzamide compound for inhibiting Bcl-2 protein and composition and application thereof
US11267806B2 (en) 2017-06-26 2022-03-08 Shenzhen Targetrx, Inc. Indazole compound for use in inhibiting kinase activity, composition and application thereof
CN111093627B (en) 2017-07-11 2024-03-08 吉利德科学公司 Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections
EP3666774B1 (en) 2017-08-11 2022-05-11 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor
CN108947974B (en) 2017-08-30 2020-06-05 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound, composition containing aminopyrimidine compound and application of aminopyrimidine compound
CN111263767B (en) 2017-08-30 2023-07-18 北京轩义医药科技有限公司 Cyclic dinucleotides as stimulators of interferon gene modulators
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
CN111201223B (en) 2017-09-11 2024-07-09 克鲁松制药公司 Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2
TW201920108A (en) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
JP7085242B2 (en) 2017-12-21 2022-06-16 深▲チェン▼市塔吉瑞生物医薬有限公司 Aryl phosphine oxide to inhibit kinase activity
WO2019120121A1 (en) 2017-12-21 2019-06-27 深圳市塔吉瑞生物医药有限公司 Diphenylaminopyrimidine compound for inhibiting kinase activity
EP3719027A4 (en) 2017-12-21 2020-12-16 Shenzhen TargetRx, Inc. Novel antiviral nucleoside reverse transcriptase inhibitor
US11447512B2 (en) 2017-12-21 2022-09-20 Shenzhen Targetrx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
BR112020012712A8 (en) 2017-12-22 2022-03-03 Sage Therapeutics Inc Compound or pharmaceutically acceptable salt thereof, pharmaceutical composition and uses of said compound for the treatment of CNS disorders
CN118772223A (en) 2017-12-22 2024-10-15 萨奇治疗股份有限公司 Compositions and methods for treating central nervous system disorders
EP3737687A1 (en) 2018-01-12 2020-11-18 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
WO2019145552A1 (en) 2018-01-29 2019-08-01 Phytoplant Research S.L Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (en) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
TW201942116A (en) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 Tetrahydroquinazoline derivatives useful as anticancer agents
TWI834637B (en) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 Piperidinyl-3-(aryloxy)propanamides and propanoates
TWI741268B (en) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 Cyclopentane-based modulators of sting (stimulator of interferon genes)
US11459334B2 (en) 2018-04-16 2022-10-04 Shenzhen Targetrx, Inc. Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors
CN113956269A (en) 2018-04-16 2022-01-21 深圳市塔吉瑞生物医药有限公司 Di (hetero) aryl macrocycles for inhibiting protein kinase activity
RU2762557C1 (en) 2018-04-26 2021-12-21 Пфайзер Инк. Derivatives of 2-aminopyridine or 2-aminopyrimidine as cyclin-dependent kinase inhibitors
US20210205299A1 (en) 2018-05-30 2021-07-08 Convert Pharmaceuticals S.A. Prodrugs and medical uses thereof
EP4241563A3 (en) 2018-06-01 2023-11-15 Bayer CropScience LP Stabilized fungicidal composition comprising cyclodextrin
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
US11840535B2 (en) 2018-07-02 2023-12-12 Shenzhen Targetrx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
WO2020011141A1 (en) 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 Diarylpyrazole compound, composition comprising same, and use thereof
EP3808746B1 (en) 2018-07-17 2023-08-02 Shenzhen TargetRx, Inc. N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
WO2020016710A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
WO2020073862A1 (en) 2018-10-10 2020-04-16 深圳市塔吉瑞生物医药有限公司 Dihydroimidazopyrazinone compound, composition including same, and use thereof
AU2019357040A1 (en) 2018-10-12 2021-05-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
EP3867261A1 (en) 2018-10-19 2021-08-25 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
AU2019387290A1 (en) 2018-11-29 2021-05-27 Pfizer Inc. Pyrazoles as modulators of hemoglobin
EP3902818A1 (en) 2018-12-05 2021-11-03 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
JP7347853B2 (en) 2018-12-06 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 Substituted pyrazolo[1,5-a]pyridine compounds, compositions containing the compounds and uses thereof
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
TWI848034B (en) 2018-12-21 2024-07-11 美商賽吉醫療公司 Neuroactive steroids and compositions thereof
WO2020125391A1 (en) 2018-12-21 2020-06-25 深圳市塔吉瑞生物医药有限公司 Aminopyrimidine compound used for inhibiting activity of protein kinase
CN113271923A (en) 2019-01-04 2021-08-17 Sq创新股份公司 Furosemide pharmaceutical composition and application thereof
KR20210116523A (en) 2019-01-14 2021-09-27 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 Tetrazolone Substituted Steroids and Uses Thereof
SG11202107226VA (en) 2019-01-23 2021-08-30 Pfizer Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
KR20210121186A (en) 2019-01-31 2021-10-07 화이자 인코포레이티드 3-carbonylamino-5-cyclopentyl-1H-pyrazole compound having inhibitory activity on CDK2
CN111574521A (en) 2019-02-18 2020-08-25 深圳市塔吉瑞生物医药有限公司 Substituted aromatic fused ring derivatives, compositions and uses thereof
WO2020173457A1 (en) 2019-02-27 2020-09-03 深圳市塔吉瑞生物医药有限公司 Substituted pyrazole compounds, compositions containing same, and use thereof
AR118471A1 (en) 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co DERIVATIVES OF PIRROL AND IMIDAZOLE FUSED WITH PYRIDINE AS INHIBITORS OF RIPK2
JP2022526917A (en) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド Ophthalmic preparations and their use
EP3946606A1 (en) 2019-03-27 2022-02-09 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
AU2020266529A1 (en) 2019-04-29 2021-12-16 Solent Therapeutics, Llc 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
JP2022530967A (en) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド Polymorphic compounds and their use
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP3967694A4 (en) 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor
BR112021026445A2 (en) 2019-06-27 2022-03-08 Sage Therapeutics Inc Compositions and Methods for Treating CNS Disorders
EP3990469A1 (en) 2019-06-27 2022-05-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US20230085354A1 (en) 2019-06-27 2023-03-16 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
KR20220044753A (en) 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 Small molecule inhibitor of acetyl coenzyme A synthetase short chain 2 (ACSS2)
MX2022001553A (en) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolone for use in treatment of status epilepticus.
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
JP2022546375A (en) 2019-08-23 2022-11-04 北京泰徳製薬股▲フン▼有限公司 Compounds that inhibit EGFR and ALK to inhibit their degradation
BR112022004819A2 (en) 2019-09-16 2022-06-07 Takeda Pharmaceuticals Co Azol-fused pyridazin-3(2h)-one derivatives
BR112022005463A2 (en) 2019-09-25 2022-06-14 Pfizer Polyheterocyclic sting modulators (interferon gene stimulator)
WO2021057877A1 (en) 2019-09-26 2021-04-01 深圳市塔吉瑞生物医药有限公司 Substituted aromatic fused ring derivative and composition comprising same, and use thereof
CN114929707B (en) 2019-11-01 2024-04-09 上海科技大学 EED inhibitor and preparation method and application thereof
KR20220134529A (en) 2019-12-06 2022-10-05 마리누스 파마슈티컬스 인코포레이티드 Ganaxolone for use in the treatment of complex tuberous sclerosis
CN114829364B (en) 2019-12-16 2023-08-22 北京泰德制药股份有限公司 Compounds that inhibit and induce degradation of EGFR kinase
EP4090650A1 (en) 2020-01-17 2022-11-23 Shengke Pharmaceuticals (Jiangsu) Ltd. Novel compounds as inhibitors of pcsk9
JP2023513241A (en) 2020-02-12 2023-03-30 キュラデブ ファーマ ピーブイティー． リミテッド Small molecule STING antagonist
JP2023518411A (en) 2020-03-18 2023-05-01 セージ セラピューティクス， インコーポレイテッド Neuroactive steroids and methods of use thereof
AR121683A1 (en) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co N-HETEROARYLALKYL-2-(HETEROCYCLIL AND HETEROCYCLILMETHYL)ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS
AR121682A1 (en) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co N-(HETEROCYCLIL AND HETEROCYCLILALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS
JP2021167301A (en) 2020-04-08 2021-10-21 ファイザー・インク Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
KR20230003128A (en) 2020-05-01 2023-01-05 화이자 인코포레이티드 Azalactam compounds as HPK1 inhibitors
CA3182379A1 (en) 2020-05-04 2021-11-11 Takeda Pharmaceutical Company Limited Luminally-acting n-(piperidin-4-yl)benzamide derivatives
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
JP2023526016A (en) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド Pharmaceutical formulations and their uses
CN115551860A (en) 2020-05-20 2022-12-30 北京泰德制药股份有限公司 2,4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
JP2023531517A (en) 2020-06-24 2023-07-24 セージ セラピューティクス， インコーポレイテッド 3. alpha. -hydroxy, 17. beta. -C(O)-N-aryl substituted neuroactive steroids and compositions thereof
TW202214641A (en) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2 mutation inhibitors
EP4166556A4 (en) 2020-07-13 2024-06-26 Beijing Tide Pharmaceutical Co., Ltd. Pyrazolopyrimidine compound used as atr kinase inhibitor
WO2022013691A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
EP4204093A1 (en) 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors
TW202229239A (en) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors
EP4251634A1 (en) 2020-11-25 2023-10-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CA3213593A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
US20240208934A1 (en) 2021-04-07 2024-06-27 Lifearc Ulk1/2 inhibitors and their use thereof
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
CR20230604A (en) 2021-06-26 2024-02-19 Array Biopharma Inc Her2 mutation inhibitors
MX2024001372A (en) 2021-07-28 2024-02-27 Sage Therapeutics Inc Crystalline forms of a neuroactive steroid.
KR20240046553A (en) 2021-08-11 2024-04-09 큐라데브 파마 프라이버트 리미티드 Small molecule urea derivatives as STING antagonists
KR20240046742A (en) 2021-08-11 2024-04-09 큐라데브 파마 프라이버트 리미티드 Small molecule STING antagonists
EP4405370A1 (en) 2021-09-22 2024-07-31 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
CA3239257A1 (en) 2021-12-01 2023-06-08 Joaquin Pastor Fernandez Compounds
WO2023134266A1 (en) 2022-01-17 2023-07-20 苏州浦合医药科技有限公司 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound serving as egfr inhibitor
AU2023211928A1 (en) * 2022-01-25 2024-09-12 Leiutis Pharmaceuticals Llp Novel naproxen sodium preparations for parenteral administration
US11958917B2 (en) 2022-02-18 2024-04-16 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023165570A1 (en) 2022-03-03 2023-09-07 深圳市塔吉瑞生物医药有限公司 Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
WO2023187677A1 (en) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (en) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co FUSED PYRIDAZINE DERIVATIVES
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
CN116969851A (en) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 Ionizable lipid compounds
EP4332087A1 (en) 2022-04-29 2024-03-06 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticles
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
US20240109915A1 (en) 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors
TW202417456A (en) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 Heterocyclic compound
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
WO2024105364A1 (en) 2022-11-15 2024-05-23 Curadev Pharma Ltd Heterocyclic inhibitors of cdc-like kinases
WO2024112759A1 (en) 2022-11-21 2024-05-30 Sage Therapeutics, Inc. Negative nmda-modulating compounds and methods of use thereof
WO2024157205A1 (en) 2023-01-26 2024-08-02 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (en) * 1970-06-10 1975-02-04
EP0056995B1 (en) * 1981-01-23 1986-03-26 The Wellcome Foundation Limited Chemical complex
JPS58177949A (en) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd Clathrate compound of lankacidin-group antibiotic substance
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (en) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Water soluble mixed ether of beta-cyclodextrin, and process for its preparation
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH0651725B2 (en) * 1985-02-28 1994-07-06 メルシャン株式会社 Partially methylated cyclodextrin and method for producing the same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (en) * 1986-12-26 1996-02-28 日清製粉株式会社 Sustained-release pharmaceutical preparation
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications

Also Published As

Publication number Publication date
CA2119154C (en) 1998-06-16
WO1994002518A1 (en) 1994-02-03
EP0620828A4 (en) 1996-05-15
DE69331900T2 (en) 2003-01-16
ATE217325T1 (en) 2002-05-15
AU672814B2 (en) 1996-10-17
JP3393253B2 (en) 2003-04-07
ES2176206T3 (en) 2002-12-01
EP0620828A1 (en) 1994-10-26
JPH06511513A (en) 1994-12-22
PT620828E (en) 2002-10-31
EP0620828B1 (en) 2002-05-08
AU4779993A (en) 1994-02-14
DE69331900T3 (en) 2009-03-26
DK0620828T3 (en) 2002-08-26
EP0620828B2 (en) 2008-07-09
ES2176206T5 (en) 2008-12-01
DK0620828T4 (en) 2008-11-03
US5376645A (en) 1994-12-27
KR100279111B1 (en) 2001-03-02
MD1813B2 (en) 2001-12-31
MD1813C2 (en) 2002-08-31
RU2113442C1 (en) 1998-06-20
CA2119154A1 (en) 1994-02-03
DE69331900D1 (en) 2002-06-13
GEP19991649B (en) 1999-06-14

Similar Documents

Publication Publication Date Title
TJ275B (en) Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof
EP0512050A4 (en) Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
RU94028890A (en) COMPOSITIONS OF DERIVATIVES OF CYCLODEXTRIN, COMPOSITIONS, CONTAINING MEDICINES AND DERIVATIVES OF CYCLODEXTRINS
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
ATE225341T1 (en) PACLITAXELE SUBSTITUTED BY THIO IN 6 POSITION
SE9503143D0 (en) New preparation
MX9701342A (en) Cosolvent parenteral formulation of tirilazad.
IT1313618B1 (en) ACID DERIVATIVES 2-AMINO-BICYCLE (3.1.0) -HESAN-2,6-BICARBOXYLS AND PROCEDURE FOR THEIR PREPARATION.
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
YU17092A (en) 2,4-DIAMINOHINAZOLINA DERIVATIVES
MX9602955A (en) Process for solubilizing difficultly soluble pharmaceutical actives.
MY135119A (en) Stabilized oral suspension formulation
NO991405L (en) Coated particle formulation
HRP20010878B1 (en) Ziprasidone suspension
FR2687401B1 (en) 1,4-DIALKYLPIPERAZINE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
MXPA03005221A (en) Pharmaceutical dronedarone composition for parenteral administration.
EP0931545A3 (en) Droloxifene pharmaceutical compositions
TR200001102T2 (en) Substituted tetrahydropyrimidinene derivatives, their production and uses.
HK1051533A1 (en) Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use.
IL105276A0 (en) Pyridine derivative,its production and pharmaceutical compositions containing it
BG106151A (en) Pharmaceutical complex
ES2166411T3 (en) PROCEDURE FOR DERIVATIZING POLYGLUCOSAMINS.
HUP0300185A2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
AU5535900A (en) Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives